Alaunos Therapeutics Stock Today
| TCRT Stock | USD 1.30 0.02 1.52% |
Performance0 of 100
| Odds Of DistressOver 54
|
Alaunos Therapeutics is selling for under 1.30 as of the 7th of May 2024; that is -1.52 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 1.26. Alaunos Therapeutics has 54 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for Alaunos Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 16th of August 2022 and ending today, the 7th of May 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 24th of August 2005 | Category Healthcare | Classification Health Care |
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas. Alaunos Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 16.01 M outstanding shares of which 1.46 M shares are at this time shorted by private and institutional investors with about 23.22 trading days to cover. More on Alaunos Therapeutics
Moving together with Alaunos Stock
| 0.62 | EGRX | Eagle Pharmaceuticals | PairCorr |
| 0.66 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
Moving against Alaunos Stock
| 0.74 | QLI | Qilian International | PairCorr |
| 0.58 | SNDL | SNDL Inc Financial Report 20th of May 2024 | PairCorr |
| 0.55 | PAHC | Phibro Animal Health Fiscal Year End 4th of September 2024 | PairCorr |
| 0.54 | CGC | Canopy Growth Corp Financial Report 27th of June 2024 | PairCorr |
| 0.54 | IMCC | Im Cannabis Corp | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 8th of May 2024
Alaunos Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Alaunos Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Alaunos Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Alaunos Therapeutics report their recommendations after researching Alaunos Therapeutics' financial statements, talking to executives and customers, or listening in on Alaunos Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Alaunos Therapeutics. The Alaunos consensus assessment is calculated by taking the average forecast from all of the analysts covering Alaunos Therapeutics. | ||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Alaunos Therapeutics' liquidity, profitability, solvency, and operating efficiency, Alaunos Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in June. Financial strength of Alaunos Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||
Alaunos Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Alaunos Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Alaunos Therapeutics' financial leverage. It provides some insight into what part of Alaunos Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Alaunos Therapeutics (TCRT) is traded on NASDAQ Exchange in USA. It is located in 8030 El Rio Street, Houston, TX, United States, 77054 and employs 1 people. Alaunos Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 21.14 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Alaunos Therapeutics's market, we take the total number of its shares issued and multiply it by Alaunos Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Alaunos Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 16.01 M outstanding shares of which 1.46 M shares are at this time shorted by private and institutional investors with about 23.22 trading days to cover.
Alaunos Therapeutics currently holds about 60.01 M in cash with (30.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.28.
Check Alaunos Therapeutics Probability Of Bankruptcy
Ownership AllocationAlaunos Therapeutics holds a total of 16.01 Million outstanding shares. Alaunos Therapeutics shows 14.29 percent of its outstanding shares held by insiders and 17.04 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Alaunos Ownership Details
Alaunos Stock Price Odds Analysis
Attributed to a normal probability distribution, the odds of Alaunos Therapeutics jumping above the current price in 90 days from now is about 89.44%. The Alaunos Therapeutics probability density function shows the probability of Alaunos Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Alaunos Therapeutics has a beta of -1.8321. This usually implies as returns on its benchmark rise, returns on holding Alaunos Therapeutics are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Alaunos Therapeutics is expected to outperform its benchmark. Additionally, alaunos Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Alaunos Therapeutics to move above the current price in 90 days from now is about 89.44 (This Alaunos Therapeutics probability density function shows the probability of Alaunos Stock to fall within a particular range of prices over 90 days) .
Alaunos Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Alaunos Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Alaunos Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Alaunos Therapeutics' value.| Instituion | Recorded On | Shares | |
| Morgan Stanley - Brokerage Accounts | 2023-09-30 | 327.5 K | |
| Two Sigma Investments Llc | 2023-09-30 | 309.2 K | |
| Ubs Group Ag | 2023-09-30 | 261.7 K | |
| Allred Capital Management, Llc | 2023-12-31 | 253 K | |
| Group One Trading, Lp | 2023-09-30 | 232.8 K | |
| Susquehanna International Group, Llp | 2023-09-30 | 122.7 K | |
| Wells Fargo & Co | 2023-09-30 | 114.9 K | |
| Charles Schwab Investment Management Inc | 2023-09-30 | 110.3 K | |
| Franklin Resources Inc | 2023-09-30 | 107.9 K | |
| Discovery Capital Management Llc | 2023-09-30 | 15.5 M | |
| Msd Partners, L.p. | 2023-09-30 | 15.2 M |
Alaunos Therapeutics Historical Income Statement
Alaunos Therapeutics Income Statement is one of the three primary financial statements used for reporting Alaunos's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Alaunos Therapeutics revenue and expense. Alaunos Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Alaunos Therapeutics' Depreciation And Amortization is comparatively stable compared to the past year. Selling And Marketing Expenses is likely to gain to about 4.1 M in 2024, whereas Operating Income is likely to drop (29.9 M) in 2024. View More FundamentalsAlaunos Stock Against Markets
Picking the right benchmark for Alaunos Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Alaunos Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Alaunos Therapeutics is critical whether you are bullish or bearish towards Alaunos Therapeutics at a given time. Please also check how Alaunos Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Alaunos Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Rebalancing Now
Portfolio RebalancingAnalyze risk-adjusted returns against different time horizons to find asset-allocation targets |
| All Next | Launch Module |
Alaunos Therapeutics Corporate Management
Elected by the shareholders, the Alaunos Therapeutics' board of directors comprises two types of representatives: Alaunos Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alaunos. The board's role is to monitor Alaunos Therapeutics' management team and ensure that shareholders' interests are well served. Alaunos Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alaunos Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Abhishek Srivastava | VP Operations | Profile | |
| Michael Wong | Vice Officer | Profile | |
| Melinda Lackey | VP Sec | Profile | |
| Kevin Sr | CEO Director | Profile | |
| Drew Deniger | VP RD | Profile |
How to buy Alaunos Stock?
Before investing in Alaunos Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Alaunos Therapeutics. To buy Alaunos Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Alaunos Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Alaunos Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Alaunos Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Alaunos Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Alaunos Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Alaunos Stock please use our How to Invest in Alaunos Therapeutics guide.
Already Invested in Alaunos Therapeutics?
The danger of trading Alaunos Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Alaunos Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Alaunos Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Alaunos Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Alaunos Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Alaunos Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Alaunos Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Alaunos Therapeutics Stock: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Alaunos Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Alaunos Stock please use our How to Invest in Alaunos Therapeutics guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Complementary Tools for Alaunos Stock analysis
When running Alaunos Therapeutics' price analysis, check to measure Alaunos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alaunos Therapeutics is operating at the current time. Most of Alaunos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Alaunos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alaunos Therapeutics' price. Additionally, you may evaluate how the addition of Alaunos Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |
Is Alaunos Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alaunos Therapeutics. If investors know Alaunos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alaunos Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (33.00) | Quarterly Revenue Growth (0.91) | Return On Assets (0.49) | Return On Equity (1.57) |
The market value of Alaunos Therapeutics is measured differently than its book value, which is the value of Alaunos that is recorded on the company's balance sheet. Investors also form their own opinion of Alaunos Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Alaunos Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alaunos Therapeutics' market value can be influenced by many factors that don't directly affect Alaunos Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alaunos Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alaunos Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alaunos Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.